World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT01201070
Date of registration: 08/09/2010
Prospective Registration: No
Primary sponsor: University of Bari
Public title: Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery ATIII
Scientific title: Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery
Date of first enrolment: September 2009
Target sample size: 90
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT01201070
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care  
Phase:  Phase 4
Countries of recruitment
Italy
Contacts
Name:     Domenico Paparella, MD
Address: 
Telephone: +39 080 559 5075
Email: dpaparella@cardiochir.uniba.it
Affiliation: 
Name:     Paparella, MD
Address: 
Telephone:
Email: dpaparella@cardiochir.uniba.it
Affiliation: 
Name:     Domenico Paparella, Investigator
Address: 
Telephone:
Email:
Affiliation:  Department of Emergency and Organ Transplant, Division of Cardiac Surgery. University of Bari, Italy
Key inclusion & exclusion criteria

Inclusion Criteria:

- All patients were candidates for cardiac surgery intervention in extracorporeal
circulation

Exclusion Criteria:

- positive history for allergic reactions to AT III

- cardiac surgery "Off-Pump"

- administration of AT during surgery or within 48 h

- treatment with drugs and non-steroidal steroids within 48 h prior

- disorders of coagulation

- platelets <30,000

- pre-existing IRC in dialysis treatment

- severe liver failure

- enlistment in another trial in the last 30 days

- hypothermia

- emergency

- reopening

- length of CEC> 180 minutes

- subjects incapable of giving legal consent



Age minimum: 18 Years
Age maximum: 80 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Aortic Valve Stenosis
Acute Coronary Syndrome
Mitral Valve Insufficiency
Mitral Valve Stenosis
Aortic Valve Insufficiency
Intervention(s)
Drug: antithrombin III
Primary Outcome(s)
Number of participants with reduced bleeding, transfusion requirements and need of reintervention for bleeding as a measure of efficacy. [Time Frame: until 5 days after surgey]
Secondary Outcome(s)
Number of participants with multi organ failure as a measure of safety. [Time Frame: until 5 days after surgery]
Number of participants with wound complication as a measure of safety. [Time Frame: until 5 days after surgery]
Number of participants with delirium as a measure of safety. [Time Frame: until 5 days after surgery]
Number of participants with infection as a measure of safety. [Time Frame: until 5 days after surgery]
Secondary ID(s)
Antithrombin III
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history